Results 41 to 50 of about 11,438 (231)
Cannabinoids and Cannabinoid Receptors: The Story so Far
Like most modern molecular biology and natural product chemistry, understanding cannabinoid pharmacology centers around molecular interactions, in this case, between the cannabinoids and their putative targets, the G-protein coupled receptors (GPCRs ...
Fred Shahbazi +3 more
doaj +1 more source
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and depression are cited as either a primary or a secondary reason for the use of cannabinoids. Aim: The purpose
Ahmed Hasbi +2 more
doaj +1 more source
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand +4 more
wiley +1 more source
Micro‐QuEChERS sample preparation coupled to LC‐QQQ‐MS enabled sensitive quantification of nitazene analogs in 100 μL of plasma. The validated method provided low detection limits and was successfully applied to an authentic intoxication case involving N‐pyrrolidino protonitazene, supporting clinical and forensic toxicology workflows.
Karla A. O. Souza +7 more
wiley +1 more source
Synthetic Cannabinoids in Oral Fluid [PDF]
At the end of 2010, the U.S. Drug Enforcement Administration (DEA) used its emergency scheduling authority to temporarily control five chemicals, JWH-018, JWH-073, JWH-200, CP-47497, and cannabicyclohexanol (CP-47497 C8), often referred to as "Spice", K2, or "synthetic cannabinoids" because of their reported cannabis-like effects.
Cynthia, Coulter +2 more
openaire +2 more sources
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman +5 more
wiley +1 more source
ABSTRACT The review examines the evolution of chemical ionization mass spectrometry (CI‐MS), a technique developed in 1966 by Field and Munson. CI is a soft‐ionization method that produces more intense molecular ions with less fragmentation than electron ionization (EI).
Malvika Dutt +4 more
wiley +1 more source
Synthetic cannabinoids JWH-018, JWH-073 and AM2201 were metabolised by the fungus Cunninghamella elegans. In this article, data on individual metabolites of their retention times, mass accuracies, major product ions and structures indicated by product ...
Shimpei Watanabe +3 more
doaj +1 more source
Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications
Circadian dysregulation contributes to Alzheimer's disease through sleep disruption, clock‐gene dysfunction, neuroinflammation, impaired proteostasis, and metabolic imbalance. These alterations promote cognitive decline and disease progression, while circadian biomarkers and chronotherapeutic interventions offer opportunities for precision diagnosis ...
Bivek Singh +2 more
wiley +1 more source
ABSTRACT The use of medicinal products derived from cannabis and its synthetic analogues has grown in recent years for various health conditions, which led to an increase in systematic reviews (SR) on the topic. The objective of this overview was to identify, synthesize, and critically appraise the evidence from SR on the benefits and harms of cannabis
Rafael Leite Pacheco +5 more
wiley +1 more source

